| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| GILD - Guild Esports Plc | BUY | 2,806 @ USD 135.93 | USD 381,420 | The ETF bought 2806 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 135.93 compared to the previous average buy price of 118.539. This is 14.7% higher than average price of previous purchases of GILD. |
| VRTX - Vertex Pharmaceuticals Inc | BUY | 814 @ USD 468.41 | USD 381,286 | The ETF bought 814 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 468.41 compared to the previous average buy price of 444.227. This is 5.4% higher than average price of previous purchases of VRTX. |
| AMGN - Amgen Inc | BUY | 1,022 @ USD 344.75 | USD 352,335 | The ETF bought 1022 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 344.75 compared to the previous average buy price of 307.479. This is 12.1% higher than average price of previous purchases of AMGN. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 336 @ USD 753.55 | USD 253,193 | The ETF bought 336 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 753.55 compared to the previous average buy price of 660.955. This is 14.0% higher than average price of previous purchases of REGN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 430 @ USD 357.98 | USD 153,931 | The ETF bought 430 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 357.98 compared to the previous average buy price of 385.509. This is -7.1% lower than average price of previous purchases of ALNY. |
| INSM - Insmed Inc | BUY | 692 @ USD 156.21 | USD 108,097 | The ETF bought 692 new shares of INSM (Insmed Inc). The shares were bought for an average price of 156.21 compared to the previous average buy price of 145.702. This is 7.2% higher than average price of previous purchases of INSM. |
| BIIB - Biogen Inc | BUY | 476 @ USD 171.59 | USD 81,677 | The ETF bought 476 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 171.59 compared to the previous average buy price of 152.397. This is 12.6% higher than average price of previous purchases of BIIB. |
| ARGX - argenx NV ADR | BUY | 94 @ USD 814.74 | USD 76,586 | The ETF bought 94 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 814.74 compared to the previous average buy price of 730.165. This is 11.6% higher than average price of previous purchases of ARGX. |
| ILMN - Illumina Inc | BUY | 496 @ USD 150.28 | USD 74,539 | The ETF bought 496 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 150.28 compared to the previous average buy price of 110.376. This is 36.2% higher than average price of previous purchases of ILMN. |
| RVMD - Revolution Medicines Inc | BUY | 628 @ USD 117.63 | USD 73,872 | The ETF bought 628 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 117.63 compared to the previous average buy price of 58.2666. This is 101.9% higher than average price of previous purchases of RVMD. |
| UTHR - United Therapeutics Corporation | BUY | 140 @ USD 468.94 | USD 65,652 | The ETF bought 140 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 468.94 compared to the previous average buy price of 393.95. This is 19.0% higher than average price of previous purchases of UTHR. |
| INCY - Incyte Corporation | BUY | 638 @ USD 101.99 | USD 65,070 | The ETF bought 638 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 101.99 compared to the previous average buy price of 84.7712. This is 20.3% higher than average price of previous purchases of INCY. |
| MRNA - Moderna Inc | BUY | 1,268 @ USD 48.71 | USD 61,764 | The ETF bought 1268 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 48.71 compared to the previous average buy price of 29.4774. This is 65.2% higher than average price of previous purchases of MRNA. |
| RPRX - Royalty Pharma Plc | BUY | 1,388 @ USD 40.4 | USD 56,075 | The ETF bought 1388 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 40.4 compared to the previous average buy price of 37.1211. This is 8.8% higher than average price of previous purchases of RPRX. |
| MEDP - Medpace Holdings Inc | BUY | 92 @ USD 588.05 | USD 54,101 | The ETF bought 92 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 588.05 compared to the previous average buy price of 467.078. This is 25.9% higher than average price of previous purchases of MEDP. |
| ROIV - Roivant Sciences Ltd | BUY | 2,258 @ USD 22.58 | USD 50,986 | The ETF bought 2258 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 22.58 compared to the previous average buy price of 16.3442. This is 38.2% higher than average price of previous purchases of ROIV. |
| VTRS - Viatris Inc | BUY | 3,740 @ USD 13.21 | USD 49,405 | The ETF bought 3740 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 13.21 compared to the previous average buy price of 10.3068. This is 28.2% higher than average price of previous purchases of VTRS. |
| BBIO - BridgeBio Pharma Inc | BUY | 626 @ USD 77.87 | USD 48,747 | The ETF bought 626 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 77.87 compared to the previous average buy price of 55.3745. This is 40.6% higher than average price of previous purchases of BBIO. |
| GH - Guardant Health Inc | BUY | 420 @ USD 114.75 | USD 48,195 | The ETF bought 420 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 114.75 compared to the previous average buy price of 74.4962. This is 54.0% higher than average price of previous purchases of GH. |
| ASND - Ascendis Pharma AS | BUY | 200 @ USD 235.39 | USD 47,078 | The ETF bought 200 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 235.39 compared to the previous average buy price of 189.499. This is 24.2% higher than average price of previous purchases of ASND. |
| NBIX - Neurocrine Biosciences Inc | BUY | 324 @ USD 136.18 | USD 44,122 | The ETF bought 324 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 136.18 compared to the previous average buy price of 135.552. This is 0.5% higher than average price of previous purchases of NBIX. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 526 @ USD 80.285 | USD 42,230 | The ETF bought 526 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 80.285 compared to the previous average buy price of 59.8311. This is 34.2% higher than average price of previous purchases of IONS. |
| SNY - Sanofi ADR | BUY | 860 @ USD 47.2 | USD 40,592 | The ETF bought 860 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 47.2 compared to the previous average buy price of 49.5338. This is -4.7% lower than average price of previous purchases of SNY. |
| SMMT - Summit Therapeutics PLC | BUY | 2,418 @ USD 16.49 | USD 39,873 | The ETF bought 2418 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 16.49 compared to the previous average buy price of 19.9527. This is -17.4% lower than average price of previous purchases of SMMT. |
| EXEL - Exelixis Inc | BUY | 870 @ USD 44.27 | USD 38,515 | The ETF bought 870 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 44.27 compared to the previous average buy price of 42.0532. This is 5.3% higher than average price of previous purchases of EXEL. |
| BNTX - BioNTech SE | BUY | 328 @ USD 115.98 | USD 38,041 | The ETF bought 328 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 115.98 compared to the previous average buy price of 103.334. This is 12.2% higher than average price of previous purchases of BNTX. |
| RNA - Avidity Biosciences Inc | BUY | 490 @ USD 72.6 | USD 35,574 | The ETF bought 490 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 72.6 compared to the previous average buy price of 53.7402. This is 35.1% higher than average price of previous purchases of RNA. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 74 @ USD 480.45 | USD 35,553 | The ETF bought 74 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 480.45 compared to the previous average buy price of 426.378. This is 12.7% higher than average price of previous purchases of MDGL. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 624 @ USD 56.21 | USD 35,075 | The ETF bought 624 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 56.21 compared to the previous average buy price of 56.9032. This is -1.2% lower than average price of previous purchases of BMRN. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 198 @ USD 168.71 | USD 33,405 | The ETF bought 198 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 168.71 compared to the previous average buy price of 139.931. This is 20.6% higher than average price of previous purchases of JAZZ. |
| AXSM - Axsome Therapeutics Inc | BUY | 164 @ USD 185.96 | USD 30,497 | The ETF bought 164 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 185.96 compared to the previous average buy price of 130.493. This is 42.5% higher than average price of previous purchases of AXSM. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 442 @ USD 67.05 | USD 29,636 | The ETF bought 442 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 67.05 compared to the previous average buy price of 34.3997. This is 94.9% higher than average price of previous purchases of ARWR. |
| KRYS - Krystal Biotech Inc | BUY | 94 @ USD 281.53 | USD 26,464 | The ETF bought 94 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 281.53 compared to the previous average buy price of 190.8. This is 47.6% higher than average price of previous purchases of KRYS. |
| HALO - Halozyme Therapeutics Inc | BUY | 382 @ USD 69.22 | USD 26,442 | The ETF bought 382 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 69.22 compared to the previous average buy price of 62.969. This is 9.9% higher than average price of previous purchases of HALO. |
| PRAX - Praxis Precision Medicines Inc | BUY | 82 @ USD 311.71 | USD 25,560 | The ETF bought 82 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 311.71 compared to the previous average buy price of 147.11. This is 111.9% higher than average price of previous purchases of PRAX. |
| CYTK - Cytokinetics Inc | BUY | 398 @ USD 63.41 | USD 25,237 | The ETF bought 398 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 63.41 compared to the previous average buy price of 51.0345. This is 24.2% higher than average price of previous purchases of CYTK. |
| NUVL - Nuvalent Inc | BUY | 234 @ USD 106.44 | USD 24,907 | The ETF bought 234 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 106.44 compared to the previous average buy price of 91.1146. This is 16.8% higher than average price of previous purchases of NUVL. |
| PCVX - Vaxcyte Inc | BUY | 426 @ USD 52.73 | USD 22,463 | The ETF bought 426 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 52.73 compared to the previous average buy price of 45.4629. This is 16.0% higher than average price of previous purchases of PCVX. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 216 @ USD 102.87 | USD 22,220 | The ETF bought 216 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 102.87 compared to the previous average buy price of 86.3265. This is 19.2% higher than average price of previous purchases of RYTM. |
| IBRX - Immunitybio Inc | BUY | 3,198 @ USD 6.45 | USD 20,627 | The ETF bought 3198 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 6.45 compared to the previous average buy price of 2.84543. This is 126.7% higher than average price of previous purchases of IBRX. |
| PTCT - PTC Therapeutics Inc | BUY | 260 @ USD 75.25 | USD 19,565 | The ETF bought 260 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 75.25 compared to the previous average buy price of 63.0843. This is 19.3% higher than average price of previous purchases of PTCT. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 216 @ USD 90.37 | USD 19,520 | The ETF bought 216 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 90.37 compared to the previous average buy price of 37.8063. This is 139.0% higher than average price of previous purchases of GPCR. |
| COGT - Cogent Biosciences Inc | BUY | 498 @ USD 36.68 | USD 18,267 | The ETF bought 498 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 36.68 compared to the previous average buy price of 22.54. This is 62.7% higher than average price of previous purchases of COGT. |
| ALKS - Alkermes Plc | BUY | 536 @ USD 33.61 | USD 18,015 | The ETF bought 536 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 33.61 compared to the previous average buy price of 30.1728. This is 11.4% higher than average price of previous purchases of ALKS. |
| CRSP - Crispr Therapeutics AG | BUY | 310 @ USD 55.52 | USD 17,211 | The ETF bought 310 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 55.52 compared to the previous average buy price of 53.3596. This is 4.0% higher than average price of previous purchases of CRSP. |
| PTGX - Protagonist Therapeutics Inc | BUY | 204 @ USD 83.1 | USD 16,952 | The ETF bought 204 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 83.1 compared to the previous average buy price of 67.2916. This is 23.5% higher than average price of previous purchases of PTGX. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 308 @ USD 53.18 | USD 16,379 | The ETF bought 308 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 53.18 compared to the previous average buy price of 40.1688. This is 32.4% higher than average price of previous purchases of CRNX. |
| KYMR - Kymera Therapeutics Inc | BUY | 234 @ USD 69.93 | USD 16,364 | The ETF bought 234 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 69.93 compared to the previous average buy price of 55.2427. This is 26.6% higher than average price of previous purchases of KYMR. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 166 @ USD 94.29 | USD 15,652 | The ETF bought 166 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 94.29 compared to the previous average buy price of 63.3543. This is 48.8% higher than average price of previous purchases of MIRM. |
| IMVT - Immunovant Inc | BUY | 570 @ USD 26.01 | USD 14,826 | The ETF bought 570 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 26.01 compared to the previous average buy price of 20.0202. This is 29.9% higher than average price of previous purchases of IMVT. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 550 @ USD 26.84 | USD 14,762 | The ETF bought 550 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 26.84 compared to the previous average buy price of 22.647. This is 18.5% higher than average price of previous purchases of ACAD. |
| SRRK - Scholar Rock Holding Corp | BUY | 332 @ USD 44.29 | USD 14,704 | The ETF bought 332 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 44.29 compared to the previous average buy price of 37.7664. This is 17.3% higher than average price of previous purchases of SRRK. |
| FOLD - Amicus Therapeutics Inc | BUY | 1,002 @ USD 14.27 | USD 14,299 | The ETF bought 1002 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 14.27 compared to the previous average buy price of 8.88465. This is 60.6% higher than average price of previous purchases of FOLD. |
| CGON - CG Oncology, Inc. Common stock | BUY | 262 @ USD 53.81 | USD 14,098 | The ETF bought 262 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 53.81 compared to the previous average buy price of 35.7168. This is 50.7% higher than average price of previous purchases of CGON. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 1,020 @ USD 13.39 | USD 13,658 | The ETF bought 1020 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 13.39 compared to the previous average buy price of 10.1322. This is 32.2% higher than average price of previous purchases of AMRX. |
| GRAL - GRAIL, LLC | BUY | 126 @ USD 104.9 | USD 13,217 | The ETF bought 126 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 104.9 compared to the previous average buy price of 69.2097. This is 51.6% higher than average price of previous purchases of GRAL. |
| ADMA - ADMA Biologics Inc | BUY | 772 @ USD 16.73 | USD 12,916 | The ETF bought 772 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 16.73 compared to the previous average buy price of 17.7881. This is -5.9% lower than average price of previous purchases of ADMA. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 64 @ USD 201.15 | USD 12,874 | The ETF bought 64 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 201.15 compared to the previous average buy price of 155.539. This is 29.3% higher than average price of previous purchases of LGND. |
| ACLX - Arcellx Inc | BUY | 188 @ USD 67.7 | USD 12,728 | The ETF bought 188 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 67.7 compared to the previous average buy price of 71.6914. This is -5.6% lower than average price of previous purchases of ACLX. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 178 @ USD 70.02 | USD 12,464 | The ETF bought 178 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 70.02 compared to the previous average buy price of 59.5637. This is 17.6% higher than average price of previous purchases of APGE. |
| VCYT - Veracyte Inc | BUY | 256 @ USD 42.27 | USD 10,821 | The ETF bought 256 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 42.27 compared to the previous average buy price of 36.0211. This is 17.3% higher than average price of previous purchases of VCYT. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 250 @ USD 41.76 | USD 10,440 | The ETF bought 250 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 41.76 compared to the previous average buy price of 38.1354. This is 9.5% higher than average price of previous purchases of XENE. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 398 @ USD 26.2 | USD 10,428 | The ETF bought 398 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 26.2 compared to the previous average buy price of 21.0967. This is 24.2% higher than average price of previous purchases of ARQT. |
| BEAM - Beam Therapeutics Inc | BUY | 330 @ USD 31.56 | USD 10,415 | The ETF bought 330 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 31.56 compared to the previous average buy price of 22.9429. This is 37.6% higher than average price of previous purchases of BEAM. |
| TERN - Tern Plc | BUY | 292 @ USD 34.33 | USD 10,024 | The ETF bought 292 new shares of TERN (Tern Plc). The shares were bought for an average price of 34.33 compared to the previous average buy price of 14.4335. This is 137.8% higher than average price of previous purchases of TERN. |
| IDYA - Ideaya Biosciences Inc | BUY | 284 @ USD 34.8 | USD 9,883 | The ETF bought 284 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 34.8 compared to the previous average buy price of 27.4946. This is 26.6% higher than average price of previous purchases of IDYA. |
| VERA - Vera Therapeutics Inc | BUY | 208 @ USD 47.49 | USD 9,878 | The ETF bought 208 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 47.49 compared to the previous average buy price of 32.4099. This is 46.5% higher than average price of previous purchases of VERA. |
| EWTX - Edgewise Therapeutics Inc | BUY | 344 @ USD 28.61 | USD 9,842 | The ETF bought 344 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 28.61 compared to the previous average buy price of 19.0349. This is 50.3% higher than average price of previous purchases of EWTX. |
| DNLI - Denali Therapeutics Inc | BUY | 476 @ USD 20.25 | USD 9,639 | The ETF bought 476 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 20.25 compared to the previous average buy price of 16.423. This is 23.3% higher than average price of previous purchases of DNLI. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 138 @ USD 68.36 | USD 9,434 | The ETF bought 138 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 68.36 compared to the previous average buy price of 59.0224. This is 15.8% higher than average price of previous purchases of TARS. |
| IRON - Ironveld Plc | BUY | 122 @ USD 76.33 | USD 9,312 | The ETF bought 122 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 76.33 compared to the previous average buy price of 67.2821. This is 13.4% higher than average price of previous purchases of IRON. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 496 @ USD 18.55 | USD 9,201 | The ETF bought 496 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 18.55 compared to the previous average buy price of 13.9743. This is 32.7% higher than average price of previous purchases of ADPT. |
| ERAS - Erasca Inc | BUY | 922 @ USD 9.96 | USD 9,183 | The ETF bought 922 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 9.96 compared to the previous average buy price of 2.82225. This is 252.9% higher than average price of previous purchases of ERAS. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 186 @ USD 48.25 | USD 8,975 | The ETF bought 186 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 48.25 compared to the previous average buy price of 41.0044. This is 17.7% higher than average price of previous purchases of SUPN. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 410 @ USD 21.75 | USD 8,918 | The ETF bought 410 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 21.75 compared to the previous average buy price of 21.2343. This is 2.4% higher than average price of previous purchases of APLS. |
| TVTX - Travere Therapeutics Inc | BUY | 290 @ USD 29.44 | USD 8,538 | The ETF bought 290 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 29.44 compared to the previous average buy price of 25.0766. This is 17.4% higher than average price of previous purchases of TVTX. |
| TWST - Twist Bioscience Corp | BUY | 198 @ USD 42.94 | USD 8,502 | The ETF bought 198 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 42.94 compared to the previous average buy price of 35.2164. This is 21.9% higher than average price of previous purchases of TWST. |
| TXG - 10X Genomics Inc | BUY | 378 @ USD 22.38 | USD 8,460 | The ETF bought 378 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 22.38 compared to the previous average buy price of 14.4679. This is 54.7% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 378 @ USD 22.38 | USD 8,460 | The ETF bought 378 new shares of TXG (Terex Corporation). The shares were bought for an average price of 22.38 compared to the previous average buy price of 14.4679. This is 54.7% higher than average price of previous purchases of TXG. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 256 @ USD 32.78 | USD 8,392 | The ETF bought 256 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 32.78 compared to the previous average buy price of 27.0859. This is 21.0% higher than average price of previous purchases of MLYS. |
| DYN - Dyne Therapeutics Inc | BUY | 464 @ USD 18 | USD 8,352 | The ETF bought 464 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 18 compared to the previous average buy price of 15.1941. This is 18.5% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 464 @ USD 18 | USD 8,352 | The ETF bought 464 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 18 compared to the previous average buy price of 15.1941. This is 18.5% higher than average price of previous purchases of DYN. |
| SYRE - Spyre Therapeutics Inc. | BUY | 252 @ USD 32.035 | USD 8,073 | The ETF bought 252 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 32.035 compared to the previous average buy price of 25.5943. This is 25.2% higher than average price of previous purchases of SYRE. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 314 @ USD 25.27 | USD 7,935 | The ETF bought 314 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 25.27 compared to the previous average buy price of 19.9056. This is 26.9% higher than average price of previous purchases of CNTA. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 1,670 @ USD 4.73 | USD 7,899 | The ETF bought 1670 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.73 compared to the previous average buy price of 5.23134. This is -9.6% lower than average price of previous purchases of RXRX. |
| RARE - Ultragenyx | BUY | 314 @ USD 24.21 | USD 7,602 | The ETF bought 314 new shares of RARE (Ultragenyx). The shares were bought for an average price of 24.21 compared to the previous average buy price of 34.3429. This is -29.5% lower than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 314 @ USD 24.21 | USD 7,602 | The ETF bought 314 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 24.21 compared to the previous average buy price of 34.3429. This is -29.5% lower than average price of previous purchases of RARE. |
| WVE - Wave Life Sciences Ltd | BUY | 542 @ USD 13.47 | USD 7,301 | The ETF bought 542 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 13.47 compared to the previous average buy price of 9.00668. This is 49.6% higher than average price of previous purchases of WVE. |
| SRPT - Sarepta Therapeutics Inc | BUY | 340 @ USD 21.13 | USD 7,184 | The ETF bought 340 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 21.13 compared to the previous average buy price of 29.3842. This is -28.1% lower than average price of previous purchases of SRPT. |
| OCUL - Ocular Therapeutix Inc | BUY | 692 @ USD 10.27 | USD 7,107 | The ETF bought 692 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 10.27 compared to the previous average buy price of 11.0389. This is -7.0% lower than average price of previous purchases of OCUL. |
| HRMY - Harmony Biosciences Holdings | BUY | 188 @ USD 36.82 | USD 6,922 | The ETF bought 188 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 36.82 compared to the previous average buy price of 33.8127. This is 8.9% higher than average price of previous purchases of HRMY. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 256 @ USD 25.23 | USD 6,459 | The ETF bought 256 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 25.23 compared to the previous average buy price of 14.3795. This is 75.5% higher than average price of previous purchases of OLMA. |
| GMAB - Genmab AS | BUY | 190 @ USD 33.88 | USD 6,437 | The ETF bought 190 new shares of GMAB (Genmab AS). The shares were bought for an average price of 33.88 compared to the previous average buy price of 28.7626. This is 17.8% higher than average price of previous purchases of GMAB. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 428 @ USD 14.53 | USD 6,219 | The ETF bought 428 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 14.53 compared to the previous average buy price of 11.878. This is 22.3% higher than average price of previous purchases of AUPH. |
| VCEL - Vericel Corp Ord | BUY | 164 @ USD 37.85 | USD 6,207 | The ETF bought 164 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 37.85 compared to the previous average buy price of 39.6139. This is -4.5% lower than average price of previous purchases of VCEL. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 146 @ USD 42.2 | USD 6,161 | The ETF bought 146 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 42.2 compared to the previous average buy price of 33.8803. This is 24.6% higher than average price of previous purchases of KNSA. |
| ARDX - Ardelyx Inc | BUY | 790 @ USD 7.77 | USD 6,138 | The ETF bought 790 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 7.77 compared to the previous average buy price of 5.17878. This is 50.0% higher than average price of previous purchases of ARDX. |
| NRIX - Nurix Therapeutics Inc | BUY | 330 @ USD 18.56 | USD 6,125 | The ETF bought 330 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 18.56 compared to the previous average buy price of 15.1678. This is 22.4% higher than average price of previous purchases of NRIX. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 72 @ USD 82.99 | USD 5,975 | The ETF bought 72 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 82.99 compared to the previous average buy price of 76.7491. This is 8.1% higher than average price of previous purchases of ANIP. |
| DVAX - Dynavax Technologies Corporation | BUY | 382 @ USD 15.51 | USD 5,925 | The ETF bought 382 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 15.51 compared to the previous average buy price of 11.343. This is 36.7% higher than average price of previous purchases of DVAX. |
| PHVS - Pharvaris BV | BUY | 208 @ USD 27.98 | USD 5,820 | The ETF bought 208 new shares of PHVS (Pharvaris BV). The shares were bought for an average price of 27.98 compared to the previous average buy price of 25.454. This is 9.9% higher than average price of previous purchases of PHVS. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 282 @ USD 20.25 | USD 5,711 | The ETF bought 282 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 20.25 compared to the previous average buy price of 14.9607. This is 35.4% higher than average price of previous purchases of SNDX. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 244 @ USD 23.24 | USD 5,671 | The ETF bought 244 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 23.24 compared to the previous average buy price of 18.2643. This is 27.2% higher than average price of previous purchases of ZYME. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 356 @ USD 15.76 | USD 5,611 | The ETF bought 356 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 15.76 compared to the previous average buy price of 9.62788. This is 63.7% higher than average price of previous purchases of AMLX. |
| NTLA - Intellia Therapeutics Inc | BUY | 376 @ USD 14.63 | USD 5,501 | The ETF bought 376 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 14.63 compared to the previous average buy price of 11.5268. This is 26.9% higher than average price of previous purchases of NTLA. |
| STOK - Stoke Therapeutics Inc | BUY | 186 @ USD 29.46 | USD 5,480 | The ETF bought 186 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 29.46 compared to the previous average buy price of 21.1682. This is 39.2% higher than average price of previous purchases of STOK. |
| PGEN - Precigen Inc | BUY | 1,146 @ USD 4.76 | USD 5,455 | The ETF bought 1146 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 4.76 compared to the previous average buy price of 3.17457. This is 49.9% higher than average price of previous purchases of PGEN. |
| MNKD - MannKind Corp | BUY | 998 @ USD 5.46 | USD 5,449 | The ETF bought 998 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.46 compared to the previous average buy price of 5.02806. This is 8.6% higher than average price of previous purchases of MNKD. |
| AGIO - Agios Pharm | BUY | 190 @ USD 28.54 | USD 5,423 | The ETF bought 190 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 28.54 compared to the previous average buy price of 33.1005. This is -13.8% lower than average price of previous purchases of AGIO. |
| HROW - Harrow Health Inc | BUY | 120 @ USD 44.47 | USD 5,336 | The ETF bought 120 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 44.47 compared to the previous average buy price of 38.5148. This is 15.5% higher than average price of previous purchases of HROW. |
| RAPT - RAPT Therapeutics Inc | BUY | 92 @ USD 57.63 | USD 5,302 | The ETF bought 92 new shares of RAPT (RAPT Therapeutics Inc). The shares were bought for an average price of 57.63 compared to the previous average buy price of 35.1304. This is 64.0% higher than average price of previous purchases of RAPT. |
| LEGN - Legend Biotech Corp | BUY | 274 @ USD 19.01 | USD 5,209 | The ETF bought 274 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 19.01 compared to the previous average buy price of 31.1916. This is -39.1% lower than average price of previous purchases of LEGN. |
| TNGX - Tango Therapeutics Inc | BUY | 438 @ USD 11.71 | USD 5,129 | The ETF bought 438 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 11.71 compared to the previous average buy price of 8.24673. This is 42.0% higher than average price of previous purchases of TNGX. |
| QURE - Uniqure NV | BUY | 204 @ USD 25.08 | USD 5,116 | The ETF bought 204 new shares of QURE (Uniqure NV). The shares were bought for an average price of 25.08 compared to the previous average buy price of 23.5951. This is 6.3% higher than average price of previous purchases of QURE. |
| FTRE - Fortrea Holdings Inc. | BUY | 300 @ USD 16.83 | USD 5,049 | The ETF bought 300 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 16.83 compared to the previous average buy price of 9.64202. This is 74.5% higher than average price of previous purchases of FTRE. |
| IMCR - Immunocore Holdings Ltd | BUY | 142 @ USD 35.11 | USD 4,986 | The ETF bought 142 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 35.11 compared to the previous average buy price of 34.1847. This is 2.7% higher than average price of previous purchases of IMCR. |
| ELVN - Enliven Therapeutics Inc. | BUY | 192 @ USD 25.78 | USD 4,950 | The ETF bought 192 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 25.78 compared to the previous average buy price of 21.6226. This is 19.2% higher than average price of previous purchases of ELVN. |
| NVCR - Novocure Ltd | BUY | 364 @ USD 13.45 | USD 4,896 | The ETF bought 364 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 13.45 compared to the previous average buy price of 15.2313. This is -11.7% lower than average price of previous purchases of NVCR. |
| NVAX - Novavax Inc | BUY | 530 @ USD 9.17 | USD 4,860 | The ETF bought 530 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 9.17 compared to the previous average buy price of 7.31345. This is 25.4% higher than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 530 @ USD 9.17 | USD 4,860 | The ETF bought 530 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 9.17 compared to the previous average buy price of 7.31345. This is 25.4% higher than average price of previous purchases of NVAX. |
| INVA - Innoviva Inc | BUY | 244 @ USD 19.56 | USD 4,773 | The ETF bought 244 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 19.56 compared to the previous average buy price of 19.6687. This is -0.6% lower than average price of previous purchases of INVA. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 686 @ USD 6.79 | USD 4,658 | The ETF bought 686 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 6.79 compared to the previous average buy price of 7.89835. This is -14.0% lower than average price of previous purchases of BCRX. |
| COLL - Collegium Pharmaceutical Inc | BUY | 102 @ USD 45.5 | USD 4,641 | The ETF bought 102 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 45.5 compared to the previous average buy price of 37.1168. This is 22.6% higher than average price of previous purchases of COLL. |
| ANAB - AnaptysBio Inc | BUY | 90 @ USD 47.54 | USD 4,279 | The ETF bought 90 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 47.54 compared to the previous average buy price of 30.8772. This is 54.0% higher than average price of previous purchases of ANAB. |
| RLAY - Relay Therapeutics Inc | BUY | 566 @ USD 7.43 | USD 4,205 | The ETF bought 566 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 7.43 compared to the previous average buy price of 5.22772. This is 42.1% higher than average price of previous purchases of RLAY. |
| SANA - Sana Biotechnology Inc | BUY | 866 @ USD 4.83 | USD 4,183 | The ETF bought 866 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 4.83 compared to the previous average buy price of 3.64605. This is 32.5% higher than average price of previous purchases of SANA. |
| TSHA - Taysha Gene Therapies Inc | BUY | 894 @ USD 4.66 | USD 4,166 | The ETF bought 894 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 4.66 compared to the previous average buy price of 3.45481. This is 34.9% higher than average price of previous purchases of TSHA. |
| ABCL - Abcellera Biologics Inc | BUY | 972 @ USD 4.24 | USD 4,121 | The ETF bought 972 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 4.24 compared to the previous average buy price of 3.87117. This is 9.5% higher than average price of previous purchases of ABCL. |
| CSTL - Castle Biosciences Inc | BUY | 96 @ USD 42.24 | USD 4,055 | The ETF bought 96 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 42.24 compared to the previous average buy price of 28.5353. This is 48.0% higher than average price of previous purchases of CSTL. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 544 @ USD 7.44 | USD 4,047 | The ETF bought 544 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 7.44 compared to the previous average buy price of 6.41509. This is 16.0% higher than average price of previous purchases of XERS. |
| SVRA - Savara Inc | BUY | 668 @ USD 6.02 | USD 4,021 | The ETF bought 668 new shares of SVRA (Savara Inc). The shares were bought for an average price of 6.02 compared to the previous average buy price of 4.49781. This is 33.8% higher than average price of previous purchases of SVRA. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 334 @ USD 11.95 | USD 3,991 | The ETF bought 334 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 11.95 compared to the previous average buy price of 8.10511. This is 47.4% higher than average price of previous purchases of DAWN. |
| AMPH - Amphastar P | BUY | 150 @ USD 25.92 | USD 3,888 | The ETF bought 150 new shares of AMPH (Amphastar P). The shares were bought for an average price of 25.92 compared to the previous average buy price of 26.0329. This is -0.4% lower than average price of previous purchases of AMPH. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 316 @ USD 11.99 | USD 3,789 | The ETF bought 316 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 11.99 compared to the previous average buy price of 10.8338. This is 10.7% higher than average price of previous purchases of ORIC. |
| GRFS - Grifols SA ADR | BUY | 402 @ USD 9.22 | USD 3,706 | The ETF bought 402 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 9.22 compared to the previous average buy price of 9.14435. This is 0.8% higher than average price of previous purchases of GRFS. |
| VIR - Vir Biotechnology Inc | BUY | 454 @ USD 7.56 | USD 3,432 | The ETF bought 454 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 7.56 compared to the previous average buy price of 5.96415. This is 26.8% higher than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 454 @ USD 7.56 | USD 3,432 | The ETF bought 454 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 7.56 compared to the previous average buy price of 5.96415. This is 26.8% higher than average price of previous purchases of VIR. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 1,290 @ USD 2.64 | USD 3,406 | The ETF bought 1290 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2.64 compared to the previous average buy price of 2.39281. This is 10.3% higher than average price of previous purchases of IOVA. |
| TBPH - Theravance Biopharma Inc | BUY | 166 @ USD 20.24 | USD 3,360 | The ETF bought 166 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 20.24 compared to the previous average buy price of 14.5928. This is 38.7% higher than average price of previous purchases of TBPH. |
| VTYX - Ventyx Biosciences Inc | BUY | 238 @ USD 14.03 | USD 3,339 | The ETF bought 238 new shares of VTYX (Ventyx Biosciences Inc). The shares were bought for an average price of 14.03 compared to the previous average buy price of 13.6376. This is 2.9% higher than average price of previous purchases of VTYX. |
| SPRY - Silverback Therapeutics Inc | BUY | 326 @ USD 10.21 | USD 3,328 | The ETF bought 326 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 10.21 compared to the previous average buy price of 12.1298. This is -15.8% lower than average price of previous purchases of SPRY. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 236 @ USD 13.5 | USD 3,186 | The ETF bought 236 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 13.5 compared to the previous average buy price of 11.2154. This is 20.4% higher than average price of previous purchases of PHAT. |
| XNCR - Xencor Inc | BUY | 236 @ USD 12.78 | USD 3,016 | The ETF bought 236 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 12.78 compared to the previous average buy price of 12.7146. This is 0.5% higher than average price of previous purchases of XNCR. |
| PCRX - Pacira BioSciences, Inc. | BUY | 144 @ USD 20.67 | USD 2,976 | The ETF bought 144 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 20.67 compared to the previous average buy price of 23.3501. This is -11.5% lower than average price of previous purchases of PCRX. |
| JANX - Janux Therapeutics Inc | BUY | 198 @ USD 14.81 | USD 2,932 | The ETF bought 198 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 14.81 compared to the previous average buy price of 24.3182. This is -39.1% lower than average price of previous purchases of JANX. |
| URGN - UroGen Pharma Ltd | BUY | 146 @ USD 20 | USD 2,920 | The ETF bought 146 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 20 compared to the previous average buy price of 17.2046. This is 16.2% higher than average price of previous purchases of URGN. |
| GERN - Geron Corporation | BUY | 2,094 @ USD 1.38 | USD 2,890 | The ETF bought 2094 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.38 compared to the previous average buy price of 1.42493. This is -3.2% lower than average price of previous purchases of GERN. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 172 @ USD 16.02 | USD 2,755 | The ETF bought 172 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 16.02 compared to the previous average buy price of 13.7699. This is 16.3% higher than average price of previous purchases of KALV. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 506 @ USD 5.23 | USD 2,646 | The ETF bought 506 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 5.23 compared to the previous average buy price of 2.48866. This is 110.2% higher than average price of previous purchases of IRWD. |
| ABUS - Arbutus Biopharma Corp | BUY | 640 @ USD 4.06 | USD 2,598 | The ETF bought 640 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.06 compared to the previous average buy price of 3.92326. This is 3.5% higher than average price of previous purchases of ABUS. |
| ARVN - Arvinas Inc | BUY | 200 @ USD 12.89 | USD 2,578 | The ETF bought 200 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 12.89 compared to the previous average buy price of 10.0643. This is 28.1% higher than average price of previous purchases of ARVN. |
| PAHC - Phibro Animal Health Corporation | BUY | 66 @ USD 39.01 | USD 2,575 | The ETF bought 66 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 39.01 compared to the previous average buy price of 31.9517. This is 22.1% higher than average price of previous purchases of PAHC. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 578 @ USD 4.43 | USD 2,561 | The ETF bought 578 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 4.43 compared to the previous average buy price of 3.88465. This is 14.0% higher than average price of previous purchases of PRME. |
| KURA - Kura Oncology Inc | BUY | 294 @ USD 8.63 | USD 2,537 | The ETF bought 294 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 8.63 compared to the previous average buy price of 8.39773. This is 2.8% higher than average price of previous purchases of KURA. |
| CGEM - Cullinan Oncology LLC | BUY | 200 @ USD 12.5 | USD 2,500 | The ETF bought 200 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 12.5 compared to the previous average buy price of 9.04615. This is 38.2% higher than average price of previous purchases of CGEM. |
| PACB - Pacific Biosciences of California | BUY | 940 @ USD 2.58 | USD 2,425 | The ETF bought 940 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 2.58 compared to the previous average buy price of 1.74863. This is 47.5% higher than average price of previous purchases of PACB. |
| RGNX - Regenxbio Inc | BUY | 172 @ USD 13.79 | USD 2,372 | The ETF bought 172 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 13.79 compared to the previous average buy price of 10.755. This is 28.2% higher than average price of previous purchases of RGNX. |
| ZLAB - Zai Lab Ltd | BUY | 122 @ USD 18.33 | USD 2,236 | The ETF bought 122 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 18.33 compared to the previous average buy price of 30.4862. This is -39.9% lower than average price of previous purchases of ZLAB. |
| MGTX - MeiraGTx Holdings PLC | BUY | 270 @ USD 8.1 | USD 2,187 | The ETF bought 270 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 8.1 compared to the previous average buy price of 7.4279. This is 9.0% higher than average price of previous purchases of MGTX. |
| REPL - Replimune Group Inc | BUY | 242 @ USD 7.71 | USD 1,866 | The ETF bought 242 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 7.71 compared to the previous average buy price of 9.15542. This is -15.8% lower than average price of previous purchases of REPL. |
| PRTA - Prothena Corporation plc | BUY | 182 @ USD 10 | USD 1,820 | The ETF bought 182 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 10 compared to the previous average buy price of 9.50164. This is 5.2% higher than average price of previous purchases of PRTA. |
| LYEL - Lyell Immunopharma Inc | BUY | 72 @ USD 25.26 | USD 1,819 | The ETF bought 72 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 25.26 compared to the previous average buy price of 10.0433. This is 151.5% higher than average price of previous purchases of LYEL. |
| FULC - Fulcrum Therapeutics Inc | BUY | 168 @ USD 10.75 | USD 1,806 | The ETF bought 168 new shares of FULC (Fulcrum Therapeutics Inc). The shares were bought for an average price of 10.75 compared to the previous average buy price of 10.2365. This is 5.0% higher than average price of previous purchases of FULC. |
| KROS - Keros Therapeutics Inc | BUY | 94 @ USD 19.2 | USD 1,805 | The ETF bought 94 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 19.2 compared to the previous average buy price of 16.0095. This is 19.9% higher than average price of previous purchases of KROS. |
| ALT - Altitude Group Plc | BUY | 324 @ USD 5.5 | USD 1,782 | The ETF bought 324 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 5.5 compared to the previous average buy price of 4.8749. This is 12.8% higher than average price of previous purchases of ALT. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 452 @ USD 3.71 | USD 1,677 | The ETF bought 452 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.71 compared to the previous average buy price of 2.99004. This is 24.1% higher than average price of previous purchases of MRVI. |
| SIGA - SIGA Technologies Inc | BUY | 232 @ USD 6.64 | USD 1,540 | The ETF bought 232 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 6.64 compared to the previous average buy price of 6.62789. This is 0.2% higher than average price of previous purchases of SIGA. |
| ACRS - Aclaris Therapeutics Inc | BUY | 338 @ USD 4.5 | USD 1,521 | The ETF bought 338 new shares of ACRS (Aclaris Therapeutics Inc). The shares were bought for an average price of 4.5 compared to the previous average buy price of 2.83447. This is 58.8% higher than average price of previous purchases of ACRS. |
| GLPG - Galapagos NV ADR | BUY | 44 @ USD 34.4 | USD 1,514 | The ETF bought 44 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 34.4 compared to the previous average buy price of 29.878. This is 15.1% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 44 @ USD 34.4 | USD 1,514 | The ETF bought 44 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 34.4 compared to the previous average buy price of 29.878. This is 15.1% higher than average price of previous purchases of GLPG. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 190 @ USD 7.96 | USD 1,512 | The ETF bought 190 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 7.96 compared to the previous average buy price of 7.77175. This is 2.4% higher than average price of previous purchases of FDMT. |
| AVXL - Anavex Life Sciences Corp | BUY | 284 @ USD 5.26 | USD 1,494 | The ETF bought 284 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 5.26 compared to the previous average buy price of 7.78569. This is -32.4% lower than average price of previous purchases of AVXL. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 182 @ USD 8.01001 | USD 1,458 | The ETF bought 182 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 8.01001 compared to the previous average buy price of 5.07237. This is 57.9% higher than average price of previous purchases of VNDA. |
| CABA - Cabaletta Bio Inc | BUY | 447 @ USD 3.18 | USD 1,421 | The ETF bought 447 new shares of CABA (Cabaletta Bio Inc). The shares were bought for an average price of 3.18 compared to the previous average buy price of 2.14004. This is 48.6% higher than average price of previous purchases of CABA. |
| TRDA - Entrada Therapeutics Inc | BUY | 118 @ USD 11.43 | USD 1,349 | The ETF bought 118 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 11.43 compared to the previous average buy price of 8.38508. This is 36.3% higher than average price of previous purchases of TRDA. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 354 @ USD 3.72 | USD 1,317 | The ETF bought 354 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.72 compared to the previous average buy price of 4.62605. This is -19.6% lower than average price of previous purchases of RCKT. |
| ALLO - Allogene Therapeutics Inc | BUY | 722 @ USD 1.72 | USD 1,242 | The ETF bought 722 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.72 compared to the previous average buy price of 1.36524. This is 26.0% higher than average price of previous purchases of ALLO. |
| ACIU - AC Immune Ltd | BUY | 332 @ USD 3.7 | USD 1,228 | The ETF bought 332 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 3.7 compared to the previous average buy price of 2.65124. This is 39.6% higher than average price of previous purchases of ACIU. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 278 @ USD 4.12001 | USD 1,145 | The ETF bought 278 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 4.12001 compared to the previous average buy price of 3.25827. This is 26.4% higher than average price of previous purchases of AVIR. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 156 @ USD 6.94999 | USD 1,084 | The ETF bought 156 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 6.94999 compared to the previous average buy price of 8.06864. This is -13.9% lower than average price of previous purchases of BCYC. |
| EOLS - Evolus Inc | BUY | 202 @ USD 4.92 | USD 994 | The ETF bought 202 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 4.92 compared to the previous average buy price of 8.40155. This is -41.4% lower than average price of previous purchases of EOLS. |
| AUTL - Autolus Therapeutics Ltd | BUY | 584 @ USD 1.46 | USD 853 | The ETF bought 584 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.46 compared to the previous average buy price of 1.72397. This is -15.3% lower than average price of previous purchases of AUTL. |
| OABI - OmniAb Inc. | BUY | 408 @ USD 1.96 | USD 800 | The ETF bought 408 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 1.96 compared to the previous average buy price of 1.88688. This is 3.9% higher than average price of previous purchases of OABI. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 94 @ USD 7.53002 | USD 708 | The ETF bought 94 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 7.53002 compared to the previous average buy price of 12.1722. This is -38.1% lower than average price of previous purchases of ARCT. |
| EDIT - Editas Medicine Inc | BUY | 316 @ USD 2.16 | USD 683 | The ETF bought 316 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 2.16 compared to the previous average buy price of 2.57644. This is -16.2% lower than average price of previous purchases of EDIT. |
| VYGR - Voyager Therapeutics Inc | BUY | 168 @ USD 4 | USD 672 | The ETF bought 168 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 4 compared to the previous average buy price of 3.95169. This is 1.2% higher than average price of previous purchases of VYGR. |
| HUMA - Humacyte Inc | BUY | 534 @ USD 1.05 | USD 561 | The ETF bought 534 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 1.05 compared to the previous average buy price of 1.93316. This is -45.7% lower than average price of previous purchases of HUMA. |
| CRBU - Caribou Biosciences Inc | BUY | 286 @ USD 1.53001 | USD 438 | The ETF bought 286 new shares of CRBU (Caribou Biosciences Inc). The shares were bought for an average price of 1.53001 compared to the previous average buy price of 1.66476. This is -8.1% lower than average price of previous purchases of CRBU. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2026-01-23 this would crystalise an overall loss. |